Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA.

DiBonaventura, Marco D; Wong, William; Shah-Manek, Bijal; Schulz, Mathias

DiBonaventura, Marco D; Wong, William; Shah-Manek, Bijal; Schulz, Mathias.

Afiliación

DiBonaventura MD; Ipsos Healthcare, Global Evidence, Value & Access, New York, NY.
Wong W; Genentech, US Medical Affairs, San Francisco, CA.
Shah-Manek B; Ipsos Healthcare, Global Evidence, Value & Access, San Francisco, CA.
Schulz M; College of Pharmacy, Touro University California, CA, USA.

Onco Targets Ther ; 11: 75-82, 2018.

Article en En | MEDLINE | ID: mdl-29317835

Palabras clave

ALK inhibitor; ALK+; alectinib; anaplastic lymphoma kinase; non-small-cell lung cancer; outcomes; treatment patterns

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Onco Targets Ther Año: 2018 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Onco Targets Ther Año: 2018 Tipo del documento: Article